NASDAQ NMS - GLOBAL MARKET · ATOS
-1.63% · -$0.0400 · Vol 100.8K
After hours · updated 16:00:00 ET
Atossa Therapeutics Inc

Atossa Therapeutics Inc

Biotechnology
$2.42
Card
Relationship Map

Follow $ATOS

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ATOS by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology

snapshot unavailable for ATOS. Cause unavailable.

ATOS
Atossa Therapeutics Inc
Stale score · Wed Oct 7 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

61/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Stale score · Wed Oct 7 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ATOS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ATOS catalysts
About Atossa Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2012
Employees
14
Country
US

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.46
Day high
$2.48
Day low
$2.38
Previous close
$2.46
52W high
$17.70
-86.33% from high
52W low
$1.75
4% of range
Market cap
$24.5M
EPS
$-4.3446
Beta
-0.30
Shares out
10M
Volume
100.8K
1.69× rel vol
Avg volume
59.6K
VWAP
$2.42
Price history computed in-house
1W
+6.61%
1M
-3.78%
3M
+2.11%
1Y
-85.47%
YTD
-72.66%
SMA 50 $2.39 · above
SMA 200 $4.52 · below
52W position 4%

ATOS overview

Veridion Score
61
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ATOS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ATOS Form 4 filings
Public disclosures

Congress activity in ATOS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

ATOS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ATOS in this window.
Lobbying spend

ATOS lobbying filings, year to date.

Registered lobbying filings matched to Atossa Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ATOS in this window.
Loading news for ATOS
Analyst ratings
Sovereign unlock shows live analyst consensus for ATOS.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.